Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: A multicenter, randomized, double-blind, placebo-controlled phase IIB trial.

Dapeng Li(Ministry of Education), Ming Gao(Chinese Academy of Forestry), Xiangqian Zheng(Tianjin Medical University Cancer Institute and Hospital), Zhengang Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruochuan Cheng(Kunming Medical University), Jianwu Qin(Henan Cancer Hospital), Ping Tang(Jiaxing University), Ying Cheng(Jilin Province Tumor Hospital), Yihebali Chi(Chinese Academy of Medical Sciences & Peking Union Medical College), Rui Huang(Fujian Medical University), Zhuming Guo(Sun Yat-sen University), Yuan Zhang(Nantong University), Jun Wang(South China Agricultural University), Qiang Li(Fuzhou University), Feng Shi(Taiwan Centers for Disease Control), Jiewu Zhang(Harbin Medical University), Hui Liu(North University of China), Minghua Ge(Tianjin Medical University Cancer Institute and Hospital)
Journal of Clinical Oncology
May 20, 2019
10.1200/jco.2019.37.15_suppl.6019
Cited by 14

Related Papers

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
A chromosome conformation capture ordered sequence of the barley genome
|Nature|2017|1.6k
A physical, genetic and functional sequence assembly of the barley genome
|Nature|2012|1.5k
Graphene and graphene oxide: biofunctionalization and applications in biotechnology
|Trends in biotechnology|2011|1.5k